Risk of muscle toxicity from concomitant use of interacting drugs
| Concomitant use of interacting drugs* | No concomitant use of interacting drugs | |
|---|---|---|
| N | 2430 | 15606 |
| Person-year | 1776 | 40418 |
| Number of events | 3 | 40 |
| Proportion of total events (%) | 0.12 | 0.26 |
| Incidence per 1000 person-years (95% CI) | 1.69 (0.54 to 5.24) | 0.99 (0.73 to 1.35) |
*The number of patients who were exposed to specific interacting drugs in this study were as follows: benzafibrate (256), fenofibrate (262), clinofibrate (1), clarithromycin (1,688), erythromycin (77), telithromycin (2), fluconazole (22), itraconazole (125), fosfluconazole (31), voriconazole (11), cyclosporine (66), amiodarone (93), saquinavir/ritonavir (0), atazanavir (0), etraririne (0) and efavirenz (0).